Towards molecular imaging of multiple sclerosis

Magnetic resonance imaging (MRI) has had a profound impact on both research and clinical management of multiple sclerosis (MS), but signal changes reflect underlying neuropathology only indirectly and often non-specifically. Positron emission tomography (PET) offers the potential to complement MRI w...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2011-03, Vol.17 (3), p.262-272
Main Authors: Owen, David RJ, Piccini, Paola, Matthews, Paul M
Format: Article
Language:English
Subjects:
Biological and medical sciences
Biomarkers - analysis
Brain - diagnostic imaging
Brain - metabolism
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Humans
Magnetic Resonance Imaging
Medical sciences
Molecular Imaging - methods
Multiple Sclerosis - diagnostic imaging
Multiple Sclerosis - metabolism
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Neurology
Positron-Emission Tomography
Predictive Value of Tests
Prognosis
Radiopharmaceuticals
Sensitivity and Specificity
Severity of Illness Index
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Magnetic resonance imaging (MRI) has had a profound impact on both research and clinical management of multiple sclerosis (MS), but signal changes reflect underlying neuropathology only indirectly and often non-specifically. Positron emission tomography (PET) offers the potential to complement MRI with quantitative measures of molecularly specific markers of cellular and metabolic processes. PET radiotracers already available promise new insights into the dynamics of the innate immune response, neuronal function, neurodegeneration and remyelination. Because PET is an exquisitely sensitive technique (able to image even picomolar concentrations), only microdoses of radioligand (
ISSN:1352-4585
1477-0970
DOI:10.1177/1352458510390070